SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

05 Nov 2024 Evaluate
The revenue for the September 2024 quarter is pegged at Rs. 25297.40 millions, about 11.91% up against Rs. 22604.70 millions recorded during the year-ago period.Net Profit recorded in the quarter ended September 2024 rise to 34.84% to Rs. 6024.40  millions  compared to R. 4467.90 millions in corresponding previous quarter.Operating Profit saw a handsome growth to 8577.90 millions from 6562.50 millions in the quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 25297.40 22604.70 11.91 49330.00 43527.50 13.33 92648.09 81271.53 14.00
Other Income 1057.60 581.10 82.00 2005.90 1155.50 73.60 2666.38 1627.83 63.80
PBIDT 8577.90 6562.50 30.71 15248.20 12116.50 25.85 25917.44 18601.65 39.33
Interest 19.20 43.10 -55.45 81.80 62.80 30.25 145.70 277.48 -47.49
PBDT 8558.70 6519.40 31.28 15166.40 12053.70 25.82 25771.74 18324.17 40.64
Depreciation 854.20 770.10 10.92 1688.20 1455.20 16.01 3176.06 2695.80 17.82
PBT 7704.50 5749.30 34.01 13478.20 10598.50 27.17 22595.68 15628.37 44.58
TAX 1680.10 1281.40 31.11 2611.30 2332.80 11.94 4361.57 3145.79 38.65
Deferred Tax 367.80 163.00 125.64 215.60 300.80 -28.32 195.98 229.43 -14.58
PAT 6024.40 4467.90 34.84 10866.90 8265.70 31.47 18234.11 12482.58 46.08
Equity 400.60 400.59 0.00 400.60 400.59 0.00 400.59 400.59 0.00
PBIDTM(%) 33.91 29.03 16.80 30.91 27.84 11.04 27.97 22.89 22.22

Mankind Pharma Share Price

2148.10 24.90 (1.17%)
20-Apr-2026 15:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.00
Dr. Reddys Lab 1233.40
Cipla 1231.25
Zydus Lifesciences 936.45
Lupin 2329.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×